Technology/ Title

Hedgehog inhibitor as an anti-cancer agent

Technology Type

Biotechnology

□Device/Diagnostics

Pharmaceutical

□Others:_____________-

Contact Person

Name: Tony Chung

Title: Project Manager

Telephone(work): +886-02-7700-3800  ext. 5235

Email:

tony.chung@dcb.org.tw

2019 BioAsia

Information

Download

https://www.dcb.org.tw/posts/729

 

 

Technology Description

 

  • Field/Type : Small molecular cancer & CSC-targeted drug
  • Introduction:

DCBCO1303, a potent Smo antagonist, demonstrated Hh signaling pathway antagonist activity as well as the inhibition activity against the Smo wild-type and D473H mutant which are responsible for the resistance to GDC-0449. In the medulloblastoma allograft model (10-40 mg DCBCO1303 /kg once a day), the effective dose-related antitumor activity has been proved.

      1. A Novel and stable chemical compound (patent filed);
      2. Overcome the resistance against Hh-pathway inhibitors;
      3. In vitro potencies are superior to reference compound GDC-0449;
      4. Adequate bioavailability and half-life;
      5. Absence of obvious toxicity in animal studies.
  • Application: basal cell carcinoma and cholangiocarcinoma

 

Intellectual Property

PCT and Taiwan patent applied

Business Opportunity

Anti-cancer therapy for basal cell carcinoma and cholangiocarcinoma

 

▌技術簡介(現況)

開發與目前上市藥物vismodegib具不同Smoothened蛋白質結合位置的抑制劑,改善藥物的抗藥性,開發能同時抑制腫瘤細胞與腫瘤幹細胞的藥物,針對實質固態瘤之特殊病患治療,因此極富競爭力與市場價值。

 

▌技術規格

具專利性Hedgehog抑制劑抗癌藥物

 

▌技術特色

1.Hedgehog抑制劑抗癌藥物篩選技術平台

2.已開發之hedgehog抑制劑抗藥性的化合物(對vismodegib抗藥性Smo-D473H突變抑制活性IC50值小於50 nM)。

3.目前in vitro活性最佳化合物,於Ptch +/- Medulloblastoma Allografts in vivo Animal Model ,其腫瘤生長抑制率 (1-T/C) 可達90 %以上。於Cholangiocarcinoma (Bile duct carcinoma, 膽道癌) in vivo Xenograft Models,其腫瘤生長抑制率 (1-T/C)可達56.7%。

 

▌應用範圍

癌症治療

 

▌接受技術者具備基礎建議(設備)

具備新藥臨床開發經驗或承接能力者

 

▌接受技術者具備基礎建議(專業)

抗體臨床前開發技能。

 

▌技術分類

藥品開發

 

▌專利狀態

已申請PCT及中華民國專利


聯絡人廖宜亭

TEL02-7700-3800 # 5297

E-mailjessieliao@dcb.org.tw

 

最後更新日期:2019.03.27